ADAMTSL2 and metabolic dysfunction-associated steatotic liver disease: ADAMTSL2 was recently identified as a circulating biomarker of fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), with superior diagnostic performance compared to standard-of-care fibrosis risk-scores [6].